# US 11,079,391 B2 · Biological marker for evaluating the IL-17 pro-inflammatory functional contribution dependent level in an individual > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,079,391 B2 - Document ID: US11079391B2 - Status: Granted - Kind: B2 - Application number: 15/316,525 - Filed: 2015-06-05 - Published: 2017-06-22 - Granted: 2021-08-03 - Earliest claimed: 2014-06-06 - Assignees: Hospices Civils De Lyon; Universite Claude Bernard Lyon 1 - Applicants: Hospices Civils De Lyon; Universite Claude Bernard Lyon 1 - Inventors: Pierre Miossec; Ndieme Thiam - Web page: https://patentgrep.com/patent/US11079391B2 ## CPC - G01N 33/6869: {Interleukin} - G01N 2500/10: involving cells - G01N 2800/50: Determining the risk of developing a disease - G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis - G01N 2800/7095: Inflammation - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract The invention relates to an in vitro process for determining the functional IL-17 pro-inflammatory dependent level (IPDL) of a biological sample, comprising the following steps: a) measuring the level of an inflammatory marker produced by IL-17-sensitive cells incubated in the presence of a biological sample, b) measuring the level of said inflammatory marker produced by said cells incubated in the presence of a biological sample, in the presence of antibodies which neutralize the biological activity of IL-17, and c) determining the IPDL level, which is the difference between the level of said inflammatory marker measured in step a) and the level of said inflammatory marker measured in step b). ## Claims ### Claim 1 An in vitro process for determining a functional IL-17 pro-inflammatory dependent level (IPDL) of a biological sample chosen from plasma and serum, comprising the following steps: a) measuring a level of an inflammatory marker produced by IL-17-sensitive cells incubated in the presence of said biological sample, b) measuring the level of said inflammatory marker produced by said IL-17-sensitive cells incubated in the presence of said biological sample, in the presence of antibodies which neutralize biological activity of IL-17, and c) determining the IPDL level, which is the difference between the level of said inflammatory marker measured in step a) and the level of said inflammatory marker measured in step b). ### Claim 2 (depends on 1) The process as claimed in claim 1, said inflammatory marker being chosen from IL-6, IL-8, G CSF, GM-CSF and prostaglandin E2. ### Claim 3 (depends on 1) The process as claimed in claim 1, wherein the biological sample is a plasma sample. ### Claim 4 (depends on 3) The process as claimed in claim 3, the IL 17-sensitive cells being incubated, in each of steps a) and b), with a solution containing 10% v/v of plasma. ### Claim 5 (depends on 1) The process as claimed in claim 1, the IL-17-sensitive cells being chosen from: mesenchymal cells, and endothelial cells. ### Claim 6 (depends on 1) The process as claimed in claim 1, wherein the IL-17-sensitive cells are synoviocytes, skin fibroblasts or epithelial cells. ### Claim 7 (depends on 1) The process as claimed in claim 1, wherein the biological sample is a serum sample. ### Claim 8 (depends on 1) The process as claimed in claim 1, wherein the IL-17-sensitive cells are cells taken from an individual whose biological sample is tested. ### Claim 9 (depends on 1) The process as claimed in claim 1, the measurement of the level of said inflammatory marker being carried out, respectively in steps a) and b), by means of an immunological test. ### Claim 10 (depends on 1) The process as claimed in claim 1, the antibody which neutralizes the biological activity of IL-17 being a monoclonal antibody. ### Claim 11 (depends on 1) An in vitro process for determining the chances of a patient, suffering from a chronic inflammatory condition, of responding to a treatment comprising administering an anti-IL17 antibody, comprising the following steps: a) determining an IPDL value of a biological sample chosen from plasma and serum from said individual, by means of a process as claimed in claim 1, b) comparing the IPDL value obtained in step a) with a reference value, and c) determining from step b) the chances of a patient, suffering from the chronic inflammatory condition, of responding to the treatment comprising administering an anti-IL17 antibody. ### Claim 12 (depends on 11) The process as claimed in claim 11, characterized in that the IL-17-sensitive cells are cells taken from the individual whose biological sample is tested. ### Claim 13 (depends on 1) An in vitro process for determining the efficacy of a treatment for a chronic inflammatory condition of an individual, said treatment consisting of administering a composition comprising an anti-IL-17 antibody, comprising the following steps: a) determining an IPDL value of a biological sample chosen from plasma and serum from said individual before the start of said treatment, by means of a process as claimed in claim 1, b) determining the IPDL value of a biological sample from said individual after the start of said treatment, by means of the process as claimed in claim 1, wherein said treatment is judged to be effective when the IPDL value determined in step a) is greater than the IPDL value determined in step b), and c) determining from step b) the efficacy of the treatment for the chronic inflammatory condition of the individual. ### Claim 14 (depends on 1) An in vitro process for determining the efficacy of a treatment for a chronic inflammatory condition of an individual with a composition comprising an anti-IL-17 antibody, comprising the following steps: a) determining an IPDL value of a biological sample chosen from plasma and serum from said individual at a first instant I1 after the start of said treatment, by means of a process as claimed in claim 1, b) determining the IPDL value of a biological sample from said individual at a second instant I2, after the first instant I1, by means of the process as claimed in claim 1, wherein said treatment is judged to be effective when the IPDL value determined in step a) is greater than the IPDL value determined in step b), and c) determining from step b) the efficacy of the treatment for the chronic inflammatory condition of the individual. ### Claim 15 (depends on 1) An in vitro process for determining a risk of occurrence of a cardiovascular event in an individual suffering from a chronic inflammatory condition, comprising the following steps: a) determining an IPDL value of a biological sample chosen from plasma and serum from said individual, by means of a process as claimed in claim 1, b) comparing the IPDL value obtained in step a) with a reference value, and c) determining from step b) the risk of occurrence of the cardiovascular event in the individual suffering from the chronic inflammatory condition. ### Claim 16 (depends on 1) An in vitro process for determining a risk of bone destruction in an individual suffering from a chronic inflammatory condition, comprising the following steps: a) determining an IPDL value of a biological sample chosen from plasma and serum from said individual, by means of a process as claimed in claim 1, b) comparing the IPDL value obtained in step a) with a reference value, and c) determining from step b) the risk of bone destruction in the individual suffering from the chronic inflammatory condition. ### Claim 17 (depends on 1) The process as claimed in claim 1, characterized in that the IL-17-sensitive cells are immortalized cells. ### Claim 18 (depends on 1) An in vivo screening process for a candidate compound which is potentially an IL-17 inhibitor in a non-human animal, comprising the following steps: a) determining a IPDL value of a biological sample chosen from plasma and serum from said non-human animal before the start of a treatment with said candidate compound, by means of a process as claimed in claim 1, b) administering said candidate compound to the non-human animal, c) determining the IPDL value of a biological sample from said non-human animal after the start of said treatment, by means of the process as claimed in claim 1, wherein said candidate compound is determined to be effective for inhibiting IL-17 when the IPDL value determined in step a) is greater than the IPDL value determined in step c), and d) determining from step c) the efficacy of the candidate compound for inhibiting IL-17.